文献速递前列腺癌

靶向与系统机器人辅助经会阴MRI-TRUS融合前列腺穿刺活检对比

Targeted vs systematic robot-assisted transperineal magnetic resonance imaging-transrectal ultrasonography fusion prostate biopsy.
PubMed 文献 · BJU Int · 2018-01-15

该研究评估经会阴机器人辅助靶向穿刺(RA-TB)与系统穿刺(RA-SB)在初诊和重复活检中的表现。202例有可疑mpMRI病灶患者中,RA-TB与RA-SB对临床显著前列腺癌检出率无显著差异(80% vs 82%),但RA-TB穿刺针数减少50%。省略RA-SB与遗漏临床显著前列腺癌的显著风险相关。

要点

  • RA-TB与RA-SB对临床显著前列腺癌检出率无显著差异(80% vs 82%)。
  • RA-TB较RA-SB减少50%穿刺针数。
  • 省略RA-SB与遗漏临床显著前列腺癌的显著风险相关。

核心结论

  • 经会阴机器人辅助靶向穿刺与系统穿刺在初诊和重复活检中临床显著前列腺癌检出率相似,但靶向穿刺减少50%穿刺针数,省略系统穿刺与遗漏临床显著前列腺癌的显著风险相关。

研究设计与样本

  • 2014至2016年间接受机器人辅助经会阴前列腺穿刺的患者,穿刺前行多参数MRI(mpMRI)并按PI-RADS v2评分规划靶向穿刺,同时行系统穿刺,分析全腺体病理,共202例有可疑mpMRI病灶患者(130例初诊,72例既往经直肠超声引导穿刺阴性)。

主要发现

  • 全部前列腺癌病例(n=123)中临床显著前列腺癌占85%。
  • RA-TB与RA-SB总前列腺癌检出率分别为77% vs 84%,无显著差异。
  • RA-TB与RA-SB临床显著前列腺癌检出率分别为80% vs 82%,无显著差异。
  • RA-TB较RA-SB采样性能更优(26.4% vs 13.9%;P < 0.001)。

临床怎么用

  • 经会阴机器人辅助靶向穿刺与系统穿刺临床显著前列腺癌检出率相似,但靶向穿刺减少50%穿刺针数。
  • 省略系统穿刺与遗漏临床显著前列腺癌的显著风险相关。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the performance of transperineal robot-assisted (RA) targeted (TB) and systematic (SB) prostate biopsy in primary and repeat biopsy settings. PATIENTS AND METHODS: Patients underwent RA biopsy between 2014 and 2016. Before RA-TB, multiparametric magnetic resonance imaging (mpMRI) was performed. Prostate lesions were scored (Prostate Imaging, Reporting and Data System, version 2) and used for RA-TB planning. In addition, RA-SB was performed. Available, whole-gland pathology was analysed. RESULTS: In all, 130 patients were biopsy naive and 72 had had a previous negative transrectal ultrasonography-guided biopsy. In total, 202 patients had suspicious mpMRI lesions. Clinically significant prostate cancer was found in 85% of all prostate cancer cases (n = 123). Total and clinically significant prostate cancer detection rates for RA-TB vs RA-SB were not significantly different at 77% vs 84% and 80% vs 82%, respectively. RA-TB demonstrated a better sampling performance compared to RA-SB (26.4% vs 13.9%; P < 0.001). CONCLUSION: Transperineal RA-TB and -SB showed similar clinically significant prostate cancer detection rates in primary and repeat biopsy settings. However, RA-TB offered a 50% reduction in biopsy cores. Omitting RA-SB is associated with a significant risk of missing clinically significant prostate cancer.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Mischinger J, Kaufmann S, Russo GI, et al. Targeted vs systematic robot-assisted transperineal magnetic resonance imaging-transrectal ultrasonography fusion prostate biopsy. BJU Int. 2018. PMID: 29211932. doi:10.1111/bju.14089

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。